The exploration of novel genomic targets has led to the development of only a few potent targeted therapies, such as IDH, FLT3, or KMT2A inhibitors for genomically defined AML subsets (Appelbaum et al., 2024). The gene discussed is IDH1; the disease is acute myeloid leukemia.